



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 17 September 2024 |
| 30 October 2023 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Andrew Robert Donald Somervell |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Vice President - Products & Technology |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---------------------------------------|
| a) Options to acquire Ordinary Shares |
| b) Performance Share Rights |
| c) Ordinary Shares |
| Beneficial Interest |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|------------------------------------|
| a) 117,027 Options |
| b) 58,850 Performance Share Rights |
| c) 103,538 Ordinary Shares |
| a) 144,531 Options |
| b) 49,717 Performance Share Rights |
| c) 122,822 Ordinary Shares |
| Andrew Robert Donald Somervell |
| Andrew Robert Donald Somervell |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative(if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative,-

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal

| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|-------|
| Three |
|-------|

Details of transactions requiring disclosure-

| |
|----------------------|
| Date of transaction: |
|----------------------|

| |
|----------------------|
| a) 11 September 2024 |
| b) 11 September 2024 |
| c) 16 September 2024 |

| | |
|--|---|
| Nature of transaction: | a) Issue of Options b) Issue of Performance Share Rights c) Exercise of Performance Share Rights and issue of Ordinary Shares |
| Name of any other party or parties to the transaction (if known): | |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: | a) Nil b) Nil c) Nil |
| Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i> | a) 27,504 Options b) 10,151 Performance Share Rights c) Exercise of 19,284 Performance Share Rights and issue of 19,284 Ordinary Shares |
| Whether relevant interests were acquired or disposed of during a closed period: | |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: | |
| Date of the prior written clearance (if any): | |
| Summary of other relevant interests after acquisition or disposal: | |
| Class of quoted financial products: | |
| Nature of relevant interest: | |
| <i>For that relevant interest, -</i> | |
| Number held in class: | |
| Current registered holder(s): | |
| <i>For a derivative relevant interest, -</i> | |
| Type of derivative: | |
| Details of derivative, - | |
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): | |
| A statement as to whether the derivative is cash settled or physically settled: | |
| Maturity date of the derivative (if any): | |
| Expiry date of the derivative (if any): | |
| The price's specified terms (if any): | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | |
| <i>For that derivative relevant interest, -</i> | |
| Parties to the derivative: | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | |
| Certification | |
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. | |
| Signature of director or officer: | |
| Date of signature: | |
| or | |
| Signature of person authorised to sign on behalf of director or officer: | <i>Raelene Leonard</i> |
| Date of signature: | 17 September 2024 |
| Name and title of authorised person: | Raelene Leonard, General Counsel & Company Secretary |



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 17 September 2024 |
| 12 September 2024 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Andrew Grant Niccol |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Chief Operating Officer |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---------------------------------------|
| a) Options to acquire Ordinary Shares |
| b) Performance Share Rights |
| c) Ordinary Shares |
| Beneficial Interest |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|------------------------------------|
| a) 25,066 Options |
| b) 10,497 Performance Share Rights |
| c) 3,150 Ordinary Shares |
| a) 34,587 Options |
| b) 12,011 Performance Share Rights |
| c) 4,500 Ordinary Shares |
| Andrew Grant Niccol |
| Andrew Grant Niccol |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative(if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative,-

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal


| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|------|
| Four |
|------|

Details of transactions requiring disclosure-

| |
|----------------------|
| Date of transaction: |
|----------------------|

| |
|----------------------|
| a) 11 September 2024 |
| b) 11 September 2024 |
| c) 11 September 2024 |
| d) 16 September 2024 |

| | |
|--|---|
| Nature of transaction: | a) Issue of Options b) Issue of Performance Share Rights c) Sale of Ordinary Shares d) Exercise of Performance Share Rights and issue of Ordinary Shares |
| Name of any other party or parties to the transaction (if known): | |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: | a) Nil b) Nil c) NZD 37.56 per Ordinary Share d) Nil |
| Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i> | a) 9,521 Options b) 3,514 Performance Share Rights c) 650 Ordinary Shares d) Exercise of 2,000 Performance Share Rights and issue of 2,000 Ordinary Shares |
| Whether relevant interests were acquired or disposed of during a closed period: | |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: | |
| Date of the prior written clearance (if any): | |
| Summary of other relevant interests after acquisition or disposal: | |
| Class of quoted financial products: | |
| Nature of relevant interest: | |
| <i>For that relevant interest,-</i> | |
| Number held in class: | |
| Current registered holder(s): | |
| <i>For a derivative relevant interest,-</i> | |
| Type of derivative: | |
| Details of derivative,- | |
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): | |
| A statement as to whether the derivative is cash settled or physically settled: | |
| Maturity date of the derivative (if any): | |
| Expiry date of the derivative (if any): | |
| The price's specified terms (if any): | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | |
| <i>For that derivative relevant interest,-</i> | |
| Parties to the derivative: | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | |
| Certification | |
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. | |
| Signature of director or officer: | |
| Date of signature: | |
| or | |
| Signature of person authorised to sign on behalf of director or officer: |  |
| Date of signature: | 17 September 2024 |
| Name and title of authorised person: | Raelene Leonard, General Counsel & Company Secretary |



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 17 September 2024 |
| 26 June 2024 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Graham Andrew McLean |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Director |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---------------------|
| Ordinary Shares |
| Beneficial Interest |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|--|
| 1,100 Ordinary Shares |
| 1,900 Ordinary Shares |
| Graham Andrew McLean and Linda Farrell as trustees of McLean Superfund A/C |
| Graham Andrew McLean and Linda Farrell as trustees of McLean Superfund A/C |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative (if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative,-

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal

| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|-----|
| One |
|-----|

Details of transactions requiring disclosure-

| |
|---|
| Date of transaction: |
| Nature of transaction: |
| Name of any other party or parties to the transaction (if known): |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: |
| Number of financial products to which the transaction related: |
| If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details— |

| |
|-------------------------------|
| 12 September 2024 |
| Purchase of Ordinary Shares |
| |
| AUD 34.915 per Ordinary Share |
| 800 Ordinary Shares |

| | |
|--|--|
| Whether relevant interests were acquired or disposed of during a closed period: | |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: | |
| Date of the prior written clearance (if any): | |


Summary of other relevant interests after acquisition or disposal:

| | |
|---|--|
| Class of quoted financial products: | |
| Nature of relevant interest: | |
| <i>For that relevant interest,-</i> | |
| Number held in class: | |
| Current registered holder(s): | |
| <i>For a derivative relevant interest,-</i> | |
| Type of derivative: | |

Details of derivative,-

| | |
|---|--|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): | |
| A statement as to whether the derivative is cash settled or physically settled: | |
| Maturity date of the derivative (if any): | |
| Expiry date of the derivative (if any): | |
| The price's specified terms (if any): | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | |
| <i>For that derivative relevant interest,-</i> | |
| Parties to the derivative: | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | |

Certification

| | |
|--|--|
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. | |
| Signature of director or officer: | |
| Date of signature: | |
| or | |
| Signature of person authorised to sign on behalf of director or officer: |  |
| Date of signature: | 17 September 2024 |
| Name and title of authorised person: | Raelene Leonard, General Counsel & Company Secretary |



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 17 September 2024 |
| 12 September 2024 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Justin Peter Callahan |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Vice President - Sales & Marketing |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---------------------------------------|
| a) Options to acquire Ordinary Shares |
| b) Performance Share Rights |
| c) Ordinary Shares |
| Beneficial Interest |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|------------------------------------|
| a) 98,992 Options |
| b) 42,879 Performance Share Rights |
| c) 168,371 Ordinary Shares |
| a) 136,658 Options |
| b) 49,367 Performance Share Rights |
| c) 175,785 Ordinary Shares |
| Justin Peter Callahan |
| Justin Peter Callahan |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative(if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative,-

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal

| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|-------|
| Three |
|-------|

Details of transactions requiring disclosure-

| |
|----------------------|
| Date of transaction: |
|----------------------|

| |
|----------------------|
| a) 11 September 2024 |
| b) 11 September 2024 |
| c) 17 September 2024 |

| | |
|--|---|
| Nature of transaction: | a) Issue of Options b) Issue of Performance Share Rights c) Exercise of Performance Share Rights and issue of Ordinary Shares |
| Name of any other party or parties to the transaction (if known): | |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: | a) Nil b) Nil c) Nil |
| Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i> | a) 37,666 Options b) 13,902 Performance Share Rights c) Exercise of 7,414 Performance Share Rights and issue of 7,414 Ordinary Shares |
| Whether relevant interests were acquired or disposed of during a closed period: | |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: | |
| Date of the prior written clearance (if any): | |
| Summary of other relevant interests after acquisition or disposal: | |
| Class of quoted financial products: | |
| Nature of relevant interest: | |
| <i>For that relevant interest,-</i> | |
| Number held in class: | |
| Current registered holder(s): | |
| <i>For a derivative relevant interest,-</i> | |
| Type of derivative: | |
| Details of derivative,- | |
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): | |
| A statement as to whether the derivative is cash settled or physically settled: | |
| Maturity date of the derivative (if any): | |
| Expiry date of the derivative (if any): | |
| The price's specified terms (if any): | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | |
| <i>For that derivative relevant interest,-</i> | |
| Parties to the derivative: | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | |
| Certification | |
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. | |
| Signature of director or officer: | |
| Date of signature: | |
| or | |
| Signature of person authorised to sign on behalf of director or officer: | <i>Raelene Leonard</i> |
| Date of signature: | 17 September 2024 |
| Name and title of authorised person: | Raelene Leonard, General Counsel & Company Secretary |



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 17 September 2024 |
| 12 September 2024 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Lewis George Gradon |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Chief Executive Officer |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---------------------------------------|
| a) Options to acquire Ordinary Shares |
| b) Performance Share Rights |
| c) Ordinary Shares |
| Beneficial Interest |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|---|
| a) 385,512 Options |
| b) 172,025 Performance Share Rights |
| c) 576,317 Ordinary Shares |
| a) 470,992 Options |
| b) 159,726 Performance Share Rights |
| c) 620,165 Ordinary Shares |
| a) Lewis George Gradon |
| b) Lewis George Gradon |
| c) Lewis George Gradon; Gradon Family Trust |
| a) Lewis George Gradon |
| b) Lewis George Gradon |
| c) Lewis George Gradon; Gradon Family Trust |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative (if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative,-

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal

| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|-------|
| Three |
|-------|

Details of transactions requiring disclosure-

| | |
|--|---|
| Date of transaction: | a) 11 September 2024 b) 11 September 2024 c) 13 September 2024 |
| Nature of transaction: | a) Issue of Options b) Issue of Performance Share Rights c) Exercise of Performance Share Rights and issue of Ordinary Shares |
| Name of any other party or parties to the transaction (if known): | |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: | a) Nil b) Nil c) Nil |
| Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i> | a) 85,480 Options b) 31,549 Performance Share Rights c) Exercise of 43,848 Performance Share Rights and issue of 43,848 Ordinary Shares |
| Whether relevant interests were acquired or disposed of during a closed period: | |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: | |
| Date of the prior written clearance (if any): | |


Summary of other relevant interests after acquisition or disposal:

| | |
|---|--|
| Class of quoted financial products: | |
| Nature of relevant interest: | |
| <i>For that relevant interest,-</i> | |
| Number held in class: | |
| Current registered holder(s): | |
| <i>For a derivative relevant interest,-</i> | |
| Type of derivative: | |

Details of derivative,-

| | |
|---|--|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): | |
| A statement as to whether the derivative is cash settled or physically settled: | |
| Maturity date of the derivative (if any): | |
| Expiry date of the derivative (if any): | |
| The price's specified terms (if any): | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | |
| <i>For that derivative relevant interest,-</i> | |
| Parties to the derivative: | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | |

Certification

| | |
|--|--|
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. | |
| Signature of director or officer: | |
| Date of signature: | |
| or | |
| Signature of person authorised to sign on behalf of director or officer: |  |
| Date of signature: | 17 September 2024 |
| Name and title of authorised person: | Raelene Leonard, General Counsel & Company Secretary |



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|--|
| Fisher & Paykel Healthcare Corporation Limited |
| 17 September 2024 |
| 12 September 2024 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Lyndal Jane York |
| Fisher & Paykel Healthcare Corporation Limited |
| |
| Chief Financial Officer |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |

| |
|---------------------------------------|
| a) Options to acquire Ordinary Shares |
| b) Performance Share Rights |
| c) Ordinary Shares |
| Beneficial Interest |

For that relevant interest-

| |
|--|
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|---|
| a) 159,843 Options |
| b) 67,840 Performance Share Rights |
| c) 17,119 Ordinary Shares |
| a) 203,534 Options |
| b) 74,560 Performance Share Rights |
| c) 26,525 Ordinary Shares |
| a) Lyndal Jane York |
| b) Lyndal Jane York |
| c) Lyndal Jane York and Alexander Eric York |
| a) Lyndal Jane York |
| b) Lyndal Jane York |
| c) Lyndal Jane York and Alexander Eric York |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|--|
| |
| |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative(if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|--|
| |
| |
| |
| |
| |
| |

For that derivative, -

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|--|
| |
| |

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Three

Details of transactions requiring disclosure-

Date of transaction:

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

a) 11 September 2024

b) 11 September 2024

c) 16 September 2024

a) Issue of Options

b) Issue of Performance Share Rights

c) Exercise of Performance Share Rights and issue of Ordinary Shares

a) Nil

b) Nil

c) Nil

a) 43,691 Options

b) 16,126 Performance Share Rights

c) Exercise of 9,406 Performance Share Rights and issue of 9,406 Ordinary Shares

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:


Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:



17 September 2024

Raelene Leonard,
General Counsel & Company Secretary



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and

Name of listed issuer:

Date this disclosure made:

Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited

17 September 2024

12 September 2024

Director or senior manager giving disclosure

Full name(s):

Name of listed issuer:

Name of related body corporate (if applicable):

Position held in listed issuer:

Paul Nigel Shearer

Fisher & Paykel Healthcare Corporation Limited

International Sales Director

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:

Nature of the affected relevant interest(s):

a) Options to acquire Ordinary Shares

b) Performance Share Rights

c) Ordinary Shares

Beneficial Interest

For that relevant interest-

Number held in class before acquisition or disposal:

Number held in class after acquisition or disposal:

Current registered holder(s):

Registered holder(s) once transfers are registered:

a) 194,686 Options

b) 86,075 Performance Share Rights

c) 397,001 Ordinary Shares

a) 201,055 Options

b) 67,632 Performance Share Rights

c) 417,795 Ordinary Shares

a) Paul Nigel Shearer

b) Paul Nigel Shearer

c) Paul Nigel Shearer; Shearer Family Trust

a) Paul Nigel Shearer

b) Paul Nigel Shearer

c) Paul Nigel Shearer; Shearer Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:

Class of underlying financial products:

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price specified in the terms of the derivative (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Three

Details of transactions requiring disclosure-

| | |
|---|---|
| Date of transaction: | a) 11 September 2024 b) 11 September 2024 c) 16 September 2024 |
| Nature of transaction: | a) Issue of Options b) Issue of Performance Share Rights c) Exercise of Performance Share Rights and issue of Ordinary Shares |
| Name of any other party or parties to the transaction (if known): | |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: | a) Nil b) Nil c) Nil |
| Number of financial products to which the transaction related: | a) 6,369 Options b) 2,351 Performance Share Rights c) Exercise of 20,794 Performance Share Rights and issue of 20,794 Ordinary Shares |
| <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i> | |
| Whether relevant interests were acquired or disposed of during a closed period: | |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: | |
| Date of the prior written clearance (if any): | |

Summary of other relevant interests after acquisition or disposal:

| | |
|---|--|
| Class of quoted financial products: | |
| Nature of relevant interest: | |
| <i>For that relevant interest,-</i> | |
| Number held in class: | |
| Current registered holder(s): | |
| <i>For a derivative relevant interest,-</i> | |
| Type of derivative: | |

Details of derivative,-

| | |
|---|--|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): | |
| A statement as to whether the derivative is cash settled or physically settled: | |
| Maturity date of the derivative (if any): | |
| Expiry date of the derivative (if any): | |
| The price's specified terms (if any): | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | |
| <i>For that derivative relevant interest,-</i> | |
| Parties to the derivative: | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | |

Certification

| | |
|--|---|
| I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. | |
| Signature of director or officer: | |
| Date of signature: | |
| or | |
| Signature of person authorised to sign on behalf of director or officer: | <i>Raelene Leonard</i> |
| Date of signature: | 17 September 2024 |
| Name and title of authorised person: | Raelene Leonard, General Counsel & Company Secretary |